Fig. 4From: Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibilityA schematic overview of strategies developed for inducible CAR receptor degradation. CARs with incorporated degradation domains might be degraded or protected against degradation by a small molecule drug. In other technologies, a CAR-inhibiting protein is co-expressed with CAR to regulate CAR function based on the presence or absence of a small moleculeBack to article page